Weill Cornell Medicine and partner institutions reported Phase 3 results from PSMAddition showing that adding a targeted radiopharmaceutical earlier in the metastatic prostate cancer care pathway delayed disease progression. The study evaluated whether front-loading radiotherapy could shift outcomes compared with administering it later. The trial’s multinational design included investigators from NewYork-Presbyterian and Memorial Sloan Kettering Cancer Center, supporting broader translational relevance across treatment settings. The report moves the asset closer to consideration as a standard-of-care sequencing question rather than a later-line option. For prostate oncology development, the core signal is operational: earlier integration can create a different window for clinical benefit, potentially changing trial designs and payer discussions.